Impact of different breathing patterns on autonomic nervous system function in patients with right-ventricular or left-ventricular dysfunction or with normal cardiac functio

Not Applicable

• Conditions: I50.1; I50.0; Left ventricular failure; Congestive heart failure

• Registration Number: DRKS00013659
• Lead Sponsor: Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-15
• Study Completion: 2018-09-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

a. Age > 18 years (no age limit) (Group 1, 2 and 3)
b. able to consent (Group 1, 2 and 3)
c. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- and heart failure with reduced ejection fraction -HFrEF- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of HFrEF / PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination therapy for both PAH and HFrEF -where there was no treatment with combination therapy in PAH patients or with beta blockers or ACE Inhibitors/ARBs in HFrEF, then the reason must be documented)
d. healthy controls (matched for age and gender) with normal findings on echocardiogram, electrocardiogram and normal levels of natriuretic peptide hormone (Group 3)

Exclusion Criteria

- other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment
- severe neurological pre-existing conditions such as stroke, especially brainstem infarction
- intake of opioids
- psychiatric pre-existing conditions

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Muscular sympathetic nerve activity [Burst rate/min; Burst rate/100 beats; measured through a microneurography device produced by AD Instruments with a small needle inserted in the peroneal nerve], high frequency component of heart rate variability [%; measured through a non-invasive hemodynamic Monitor -Task Force Monitor- produced by CNSystems], low frequency component of diastolic blood pressure variability [%; measured through a non-invasive hemodynamic Monitor -Task Force Monitor- produced by CNSystems]

Secondary Outcome Measures

Name	Time	Method
Heart rate [bpm], systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], <br>-> the above mentioned will be measured through a non-invasive hemodynamic Monitor -Task Force Monitor- produced by CNSystems<br>respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG]<br>-> the above mentioned will be measured through a polysomnography device produced by Nihon Kohden<br><br>->mean values under the different interventions will be obtained and compared